Search Clinical Trials
Recruiting
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (External Link)
Transitioning from busulfan, hydroxyurea, IFN-α to tyrosine kinase inhibitors (TKIs) has dramatically altered the natural history of CML. Patients with CML appropriately managed with TKIs are able to benefit from …
Baylor Role:
Lead Sponsor